rituximab Injection [Rituxan]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The advent of monoclonal antibody biosimilar products has stimulated the development of analytical methods that can better… (More)
  • figure 1
  • figure 2
Is this relevant?
2018
2018
This report assesses the observed risk of PML in patients treated with the anti-CD20 monoclonal antibody rituximab in the… (More)
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2014
Review
2014
A paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) has taken place over the past decade, as therapies have… (More)
Is this relevant?
2010
2010
Multifocal motor neuropathy (MMN) is an acquired demyelinating motor neuropathy. Intravenous immunoglobulin (IVIg) has been found… (More)
Is this relevant?
2010
2010
Abstract 3980 Rituximab (MabThera)® is a chimeric mouse/human monoclonal antibody recognizing the B cell specific trans-membrane… (More)
Is this relevant?
2008
2008
Goals of workTargeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Review
2006
Review
2006
Rituximab (MabThera®, Rituxan®) is an anti-CD20 monoclonal antibody that induces lysis and apoptosis of normal and malignant… (More)
Is this relevant?
Review
2006
Review
2006
CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2001
2001
The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Inhibitory receptors have been proposed to modulate the in vivo cytotoxic response against tumor targets for both spontaneous and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?